Open-Label Study of Valbenazine for the Treatment of Chorea Associated With Huntington Disease in Canada
Latest Information Update: 21 May 2024
At a glance
- Drugs Valbenazine (Primary)
- Indications Chorea; Huntington's disease
- Focus Adverse reactions
- Sponsors Neurocrine Biosciences
Most Recent Events
- 14 May 2024 Planned End Date changed from 1 Mar 2026 to 1 Apr 2026.
- 14 May 2024 Planned primary completion date changed from 1 Mar 2026 to 1 Apr 2026.
- 19 Mar 2024 New trial record